PO.TB10.01 · 肿瘤生物学
致肥物共暴露通过脂肪细胞介导的机制促进三阴性乳腺癌生长
Obesogen co-exposure promotes triple-negative breast cancer growth via adipocyte-mediated mechanisms
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:双酚A(BPA)和二氯二苯二氯乙烯(DDE;DDT的主要代谢产物)是环境"致肥物",它们各自与脂肪细胞功能改变及乳腺癌风险增加相关。虽然单独致肥物的效应已得到充分研究,尤其在激素受体(HR)阳性乳腺癌中,但联合暴露的生物学后果及其通过脂肪细胞-肿瘤相互作用对HR阴性疾病的影响仍知之甚少。在此,我们研究致肥物共暴露如何改变乳腺脂肪细胞功能,并在三阴性乳腺癌(TNBC)小鼠模型中促进肿瘤发生。
研究设计:将青春期后的BALB/c小鼠(n=10/组)在整个研究期间通过饮用水暴露于致肥物,采用环境相关剂量(溶媒(乙醇);BPA(4μg/kg/天);DDE(0.8μg/kg/天);联合(BPA+DDE))。暴露2周后,将小鼠乳腺癌细胞(4T1;20,000个细胞)双侧注射入第四腹股沟乳腺脂肪垫,并在研究者盲法下追踪肿瘤生长21天。为评估致肥物如何在体外影响脂肪细胞功能,将3T3-L1前脂肪细胞在溶媒(0.03%乙醇)、BPA(1nM)、DDE(1μM)或联合(BPA+DDE)存在下进行分化,并使用脂肪因子芯片评估脂肪因子分泌谱。
结果:各处理组间小鼠体重无差异。在无肿瘤的乳腺中,致肥物暴露与脂肪细胞体积增大相关(BPA 1029±231μm²,DDE 957±350μm²,联合 1011±344μm²),相较于溶媒处理小鼠(766±187μm²;p<0.05)。有趣的是,尽管单独暴露诱导脂肪细胞肥大,但仅联合暴露相较于溶媒处理小鼠增加了上皮细胞增殖(Ki67)(2.8倍,p=0.02)。在肿瘤中,联合处理相较于溶媒处理小鼠与肿瘤负荷增加(1.4倍,p=0.02)和增殖增加(1.3倍,p=0.04)相关。在体外,致肥物暴露改变了脂肪细胞对11/38种脂肪因子的分泌(变化>2倍),其中6种为联合处理脂肪细胞所特有(上调:LIF;下调:IGF-II、VEGF、M-CSF、CCL2、脂联素)。将4T1细胞暴露于该条件培养基相较于溶媒对照增加了增殖(EdU)(1.5倍,p=0.04)。未来的研究方向将探究抑制LIF/LIFR信号传导是否可消除致肥物诱导的增殖。
结论:BPA与DDE共暴露在环境相关剂量下协同促进TNBC增殖,凸显了在真实世界共暴露背景下研究致肥物的必要性。对HR阴性疾病的效应独立于肥胖发生,且至少部分是通过脂肪细胞衍生的机制介导的,凸显了将研究范围扩展到HR阳性乳腺癌之外的必要性。
查看英文原文 English abstract
Introduction : Bisphenol A (BPA) and dichlorodiphenyldichloroethylene (DDE; the primary metabolite of DDT) are environmental ‘obesogens' that independently associate with altered adipocyte function and increased breast cancer risk. While the effects of obesogens alone are well studied, particularly in hormone receptor (HR)-positive breast cancer, the biological consequences of combined exposure and their impact on HR-negative disease through adipocyte-tumor interactions remains poorly understood. Here, we investigate how obesogen co-exposure alters mammary adipocyte function and promotes tumorigenesis in a mouse model of triple-negative breast cancer (TNBC).
Study design : Post-pubertal BALB/c mice (n=10/group) were exposed to obesogens via drinking water for the duration of the study, at environmentally relevant doses (Vehicle (ethanol); BPA (4µg/kg/day); DDE (0.8µg/kg/day); combination (BPA+DDE)). After 2 weeks exposure, murine mammary cancer cells (4T1; 20,000 cells) were injected bilaterally into the fourth inguinal mammary fat-pads, and investigator-blinded tumor growth tracked for 21 days. To assess how obesogens affect adipocyte function in vitro, 3T3-L1 preadipocytes were differentiated in the presence of vehicle (0.03% ethanol), BPA (1nM), DDE (1µM), or combination (BPA+DDE), and adipokine secretion profiles assessed using an adipokine array.
Results : Mouse body weight did not differ between treatment groups. In tumor-free mammary glands, obesogen exposure associated with increased adipocyte size (BPA 1029±231µm 2 , DDE 957±350µm 2 , Combo 1011±344µm 2 ) compared to vehicle-treated mice (766±187µm 2 ; p<0.05). Interestingly, while individual exposures induced adipocyte hypertrophy, only combined exposure increased epithelial cell proliferation (Ki67), compared to vehicle-treated mice (2.8-fold, p=0.02). In tumors, combination treatment associated with increased tumor burden (1.4-fold, p=0.02) and proliferation (1.3-fold, p=0.04), compared to vehicle-treated mice. In vitro, obesogen exposure altered adipocyte secretion of 11/38 adipokines (>2-fold change), 6 of which were unique to combination-treated adipocytes (up: LIF; down: IGF-II, VEGF, M-CSF, CCL2, adiponectin). Exposure of 4T1 cells to this conditioned media increased proliferation (EdU), compared to vehicle controls (1.5-fold, p=0.04). Future directions will investigate whether inhibition of LIF/LIFR signaling abrogates obesogen-induced proliferation.
Conclusions : Co-exposure to BPA and DDE synergistically promotes TNBC proliferation at environmentally relevant doses, underscoring the need to study obesogens in the context of real-world co-exposures. The effects on HR-negative disease occurred independent of obesity and were mediated, at least in part, through adipocyte-derived mechanisms, highlighting the need to expand research beyond HR-positive breast cancer.
利益披露 Disclosure
S. M. Bernhardt, None.